Noida, India -- (SBWire) -- 02/26/2014 --The market for monoclonal antibody is generally influenced by increasing size of potential cancer market therby prompted pharmaceutical players to invest in oncology sector. Such monoclonal antibodies are driving the cancer therapy market and have become a vital treatment option for a varied number of cancer types. Multiple applications for the same monoclonal antibody for different cancer types have also increased in the recent past. Several cancer monoclonal antibodies are in market and a lot more in pipeline specific to certain market players indicating a potential market for cancer monoclonal antibodies. However, Roche seems to be devoting major chunk of its R&D on oncology with drugs in pipeline focusing on 35 varied indications. The majority of the antibodies are in Phase III trials with an increased focus over treatment of breast cancer, tumours and NHL.
The report entitled “Cancer Monoclonal Antibodies Market Forecast to 2017”, provides an extensive study of global burden of cancer, with current and future predictions and region wise analysis. The report introduces the client to the monoclonal antibody technology, with profiles of each cancer mAb including their mechanism of action. We have also provided a country level analysis with focus on Europe, Japan and US. The segment contains current and future market predictions and latest regulatory approvals in each area. . The report also contains a segment on global anti neoplastic market consisting of current and future market share of cancer mAbs. Moreover, it provides an exhaustive study of the key players with their recent developments along with list of current and pipeline mAbs.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM620.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
ABOUT RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.
Increasing Dedication of Roche's R&D for Cancer mAbs